Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
This in vitro study tested whether an extremely low-frequency EMF (100 Hz, 100 G) could enhance temozolomide cytotoxicity in human glioma cell lines (U87 and T98G). The authors report that combined EMF and temozolomide increased apoptosis relative to either treatment alone and was accompanied by changes in apoptosis-related markers and oxidative stress indicators. The paper concludes the combination may be a potential therapeutic approach, while noting that further studies are needed to clarify mechanisms.
Key points
- The study is an in vitro experiment in two human glioma cell lines (U87 and T98G).
- Exposure involved an ELF electromagnetic field at 100 Hz and 100 G, combined with 100 μM temozolomide.
- Co-treatment reportedly increased apoptosis compared with temozolomide alone or EMF alone.
- Apoptosis-related markers shifted toward a pro-apoptotic profile (increased P53, Bax, Caspase-3; decreased Bcl-2, Cyclin-D1).
- Reactive oxygen species production increased with co-treatment compared with controls.
- HO-1 gene expression was reported to be overexpressed with co-treatment.
- Authors suggest a possible redox-related mechanism and call for further mechanistic studies.
Referenced studies & papers
Relevant papers in OpenMel
Source:
Open original
AI-generated summaries may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.
AI-generated summaries may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.
Comments
Log in to comment.
No comments yet.